Is non-coeliac gluten sensitivity real?

In a minority, under blinding, yes. Across ten double-blind placebo-controlled challenge trials covering 1,312 adults, 38 of 231 patients with suspected non-coeliac gluten sensitivity, 16 percent, showed gluten-specific symptoms. In the same pooled analysis 40 percent had a nocebo response, reporting similar or worse symptoms on placebo. There is still no biomarker and no identified mechanism, which is why blinded challenge is the only instrument available.

I feel much better without wheat. Is that gluten?

Possibly not, and there is a specific test for which it is. In a blinded crossover of gluten, fructan and placebo in 59 people already avoiding gluten, fructan produced significantly worse overall symptoms and bloating than gluten did, and gluten did not differ from placebo at all. Fructans are a FODMAP and wheat is a major source of them, so the next thing to test is fermentable carbohydrate rather than a stricter gluten exclusion.

Should I get tested for coeliac disease first?

Yes, before starting, and this is the only hard rule here. Coeliac serology and biopsy both require gluten in the diet to be valid. Going gluten free first makes the diagnosis hard to reach and can require a formal supervised gluten challenge later to get an answer. Coeliac disease is the one condition in this area with a known mechanism, a known marker and real consequences if it goes untreated.

Is a gluten free diet healthier if I don't have coeliac disease?

The one long cohort says no and explains why the question is misleading. Across 110,017 people followed 26 years, gluten intake had no association with coronary heart disease, hazard ratio 0.95, p for trend 0.29. Once refined grain intake was accounted for, higher gluten intake was associated with lower coronary risk, 0.85, because gluten intake was tracking whole grain intake. The authors conclude that gluten free diets should not be promoted in people without coeliac disease.

Is there anything I should watch if I do it anyway?

Folic acid, because wheat flour is the folic acid fortification vehicle in the US and gluten avoiders without coeliac disease had measurably lower intake in national survey data. That matters most for anyone who could become pregnant and it is entirely solvable. The other thing to watch is what replaces the wheat: gluten free replacement products are commonly refined starch with less fibre than what they replace.

Elimination8 human studies cited

Gluten free without coeliac disease

Written by Aaron CuhaReviewed Sep 2026

Also called: Gluten free diet, Non-coeliac gluten sensitivity, Wheat free

Ten blinded gluten challenge trials in 1,312 adults found gluten-specific symptoms in 16 percent of suspected cases and a nocebo response in 40 percent. In the crossover that tested them head to head, fructans produced worse symptoms than gluten did, and gluten did not differ from placebo.

What it actually is

Excluding wheat, barley and rye, and usually oats by cross-contamination, when the person doing it does not have coeliac disease and does not have a wheat allergy. That qualifier defines this entry. For coeliac disease the gluten free diet is not a lifestyle choice, it is the treatment for an autoimmune enteropathy, it is not optional and it is not what this page is about. The population here is the much larger one: people who feel better without wheat, have not been diagnosed with anything, and want to know whether gluten is the reason. A US survey series has tracked how large that group has become relative to diagnosed coeliac disease.

The mechanism its advocates propose

That gluten, the storage protein complex in those grains, triggers symptoms in people without coeliac disease through some route that is not the autoimmune one, usually called non-coeliac gluten sensitivity. The mechanism has never been identified, no biomarker exists, and the diagnosis is made by exclusion plus response to the diet. That is why blinded rechallenge carries more weight here than anywhere else on this site: with no marker to measure, a challenge trial is the only instrument available, and the competing explanation, that the agent is a fermentable carbohydrate in the same foods rather than the protein, predicts a specific and testable result.

What happened when calories were controlled

Strongest design available: controlled

Energy intake was matched between groups, so a difference in the result is attributable to the composition of the diet rather than to how much was eaten.

Calories are not the question and no calorie-controlled trial exists or is needed. The question is whether gluten is the agent, and that has been tested the right way: blinded rechallenge with the challenge material provided and a matched placebo. The answer has moved over fifteen years, from yes in the first trial to a small minority in the pooled analysis, with fructans outperforming gluten as the trigger in the trial that tested both.

Biesiekierski 2011 is the trial that established the entity. 34 patients with irritable bowel syndrome, coeliac disease excluded, already symptomatically controlled on a gluten free diet, randomised to gluten or placebo delivered as two bread slices and one muffin a day for up to six weeks. 13 of 19 on gluten reported symptoms not adequately controlled against 6 of 15 on placebo, p = 0.0001, with significantly worse overall symptoms within one week (p = 0.047), pain (0.016), bloating (0.031), stool consistency satisfaction (0.024) and tiredness (0.001). No anti-gliadin antibodies were induced and there were no changes in faecal lactoferrin, coeliac antibodies, C-reactive protein or intestinal permeability, and no difference by HLA-DQ2 or DQ8 status. The authors' own conclusion is worth quoting for its restraint: non-coeliac gluten intolerance may exist, but no clues to the mechanism were elucidated.
Biesiekierski 2013, from the same group, tested whether that result survives removing fermentable carbohydrates first. 37 participants, two weeks of reduced FODMAP diet, then high gluten at 16 g a day, low gluten at 2 g plus 14 g whey, or control at 16 g whey. Gastrointestinal symptoms improved consistently and significantly during FODMAP reduction in all participants, then worsened to a similar degree whether the added protein was gluten or whey. Gluten-specific effects appeared in 8 percent of participants. No diet-specific change in any biomarker. In a three-day rechallenge of 22 participants the gluten effect was not reproduced, and an order effect was observed.
Skodje 2018 tested gluten against fructan directly, which is the experiment the field needed. 59 people on a self-instituted gluten free diet with coeliac disease excluded, blinded crossover of gluten 5.7 g, fructan 2.1 g or placebo concealed in muesli bars for seven days each. Overall symptom scores were 33.1 on gluten, 38.6 on fructan and 34.3 on placebo, p = 0.04 across the three, with bloating at 9.3, 11.6 and 10.1, p = 0.004. Fructan was significantly worse than gluten for overall symptoms (p = 0.049) and for bloating (p = 0.003). There was no difference between gluten and placebo. 13 participants scored highest after gluten, 24 after fructan and 22 after placebo.
Zanini 2015 randomised a gluten challenge in people who met the clinical criteria for non-coeliac gluten sensitivity, and the published title carries the result: symptom recurrence in only a minority of patients.
Molina-Infante and Carroccio 2017 pooled ten double-blind placebo-controlled gluten challenge trials covering 1,312 adults. Most individual studies found gluten challenge significantly increased symptom scores against placebo. Across them, only 38 of 231 patients with suspected non-coeliac gluten sensitivity, 16 percent, showed gluten-specific symptoms, and 40 percent had a nocebo response, meaning similar or increased symptoms on placebo. The trials varied from one day to six weeks, doses ran from 2 to 52 g a day with three studies below 8 g, and the placebos included gluten-free products, xylose, whey protein, rice and corn starch containing fermentable carbohydrates. The authors' conclusion is that the findings cast doubt on gluten as the culprit food component in most patients with presumptive non-coeliac gluten sensitivity.
Not everything points the same way. A 2016 multicentre randomised double-blind placebo-controlled gluten challenge reported evidence for the presence of non-coeliac gluten sensitivity in patients with functional gastrointestinal symptoms. A real minority responding to gluten specifically is consistent with everything above; what has collapsed is the size of that minority, not its existence.
One widely circulated trial should not be used. A 2019 Gastroenterology report that gluten does not induce gastrointestinal symptoms in healthy volunteers was retracted in 2024 and is flagged as a retracted publication. It appears in summaries of this topic and it is not evidence.

What happened when people just ate it

The free-living layer is about consequences rather than symptoms, and there is one long cohort worth knowing. Lebwohl 2017 followed 64,714 women and 45,303 men without coeliac disease for 26 years, with diet assessed every four years, and documented 2,431 and 4,098 coronary heart disease events. Comparing the highest to the lowest fifth of estimated gluten intake, the unadjusted rate difference was 75 fewer coronary events per 100,000 person-years. After adjustment for known risk factors the hazard ratio was 0.95 (95% CI 0.88 to 1.02), p for trend 0.29, so no association. The informative part is what happened next: adjusting additionally for whole grain intake moved it to exactly 1.00, and adjusting instead for refined grain intake, which leaves the part of gluten intake that tracks with whole grains, produced a hazard ratio of 0.85 (0.77 to 0.93), p for trend 0.002. In other words gluten itself did nothing and gluten intake was acting as a marker for whole grain intake. The authors write that the promotion of gluten free diets among people without coeliac disease should not be encouraged. US survey data adds a nutritional footnote: among 15,610 NHANES participants aged 20 and over, people without coeliac disease who avoided gluten had lower total carbohydrate and sugar intake, higher beta-carotene and lutein and zeaxanthin, and lower folic acid intake. The folic acid finding follows directly from fortification policy, because in the US wheat flour is the vehicle for folic acid fortification.

Protein, and whether it confounds the result

Gluten is a protein, and removing it removes a protein source, but a nutritionally minor one in most diets and one nobody has measured as a protein intake outcome in people without coeliac disease. No trial here reported protein intake or lean mass. The measurable nutritional consequence of the pattern is not protein at all, it is what replaces the grain: in US survey data, people without coeliac disease avoiding gluten had lower folic acid intake, which follows from wheat flour being the fortification vehicle rather than from anything about gluten. Anyone combining this pattern with a training programme gets no protein guidance from it, and the practical issue is that many gluten free replacement products are refined starch with less protein and less fibre than what they replace.

The measured intakes behind the protein figures are on the protein page.

What reliably moves

Marker	Direction	From
Symptoms on blinded gluten rechallenge	Worse in a minority, and the minority is smaller than the diet's popularity suggests	16 percent of 231 suspected cases across ten pooled trials showed gluten-specific symptoms. 40 percent showed a nocebo response, with similar or increased symptoms on placebo.
Symptoms on blinded fructan rechallenge	Worse than on gluten	Overall symptom score 38.6 on fructan against 33.1 on gluten (p = 0.049) and bloating 11.6 against 9.3 (p = 0.003), with gluten not differing from placebo. For someone who feels better off wheat, this is the most useful finding here and it points at the low FODMAP entry rather than at gluten.
Intestinal permeability, faecal lactoferrin, C-reactive protein, coeliac and anti-gliadin antibodies	Unchanged	All measured in the trial that established the entity and none of them moved, including in the participants whose symptoms clearly worsened. There is still no biomarker for this condition.
Coronary heart disease over 26 years	No association with gluten intake	Hazard ratio 0.95 (0.88 to 1.02) across 110,017 people, moving to 1.00 after adjusting for whole grains and to 0.85 after adjusting for refined grains. Gluten intake was behaving as a proxy for whole grain intake.
Folic acid intake	Down	Lower in people without coeliac disease avoiding gluten, in a national survey of 15,610 adults, which follows from wheat flour being the folic acid fortification vehicle in the US. Their beta-carotene and lutein and zeaxanthin intakes were higher.
Coeliac serology	Becomes uninterpretable	Not a marker that moves so much as a diagnostic that breaks. Coeliac antibody testing and biopsy require gluten in the diet to be valid, so going gluten free before testing removes the ability to make or exclude the diagnosis without a formal gluten challenge later.

Long term, and hard outcomes

No randomised trial in people without coeliac disease has run beyond six weeks and none has measured a hard outcome. The longest data anywhere is the 26-year cohort finding no association between gluten intake and coronary heart disease, and finding that the apparent association reversed direction once refined grain intake was accounted for, which is an argument about whole grains rather than about gluten. What that leaves is a pattern with no demonstrated long-term benefit in this population, one documented nutritional cost in fortified-flour countries, and one documented diagnostic cost that is larger than it looks: the longer someone eats gluten free without being tested, the harder coeliac disease becomes to diagnose, and coeliac disease is the one condition in this area with a known mechanism, a known marker and a known consequence if untreated. The honest summary is that a minority of people do react to gluten specifically under blinding, that most people who believe they do turn out not to under blinding, that a good proportion react to the fructans in the same foods, and that a substantial fraction react to placebo.

Citations

Human2011
Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial.
American Journal of Gastroenterology
34 patients with irritable bowel syndrome, coeliac disease excluded, controlled on a gluten free diet, randomised to gluten or placebo bread and muffins for up to six weeks. 13 of 19 on gluten reported inadequate symptom control against 6 of 15 on placebo, p = 0.0001. No anti-gliadin antibodies induced and no change in faecal lactoferrin, coeliac antibodies, C-reactive protein or intestinal permeability, and no difference by DQ2 or DQ8 status.
Human2013
No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates.
Gastroenterology
37 participants, crossover. Symptoms improved consistently on FODMAP reduction then worsened to a similar degree whether the added protein was gluten or whey. Gluten-specific effects in 8 percent. No diet-specific change in any biomarker, and a three-day rechallenge in 22 participants did not reproduce a gluten effect. An order effect was observed.
Human2018
Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity.
Gastroenterology
59 people on a self-instituted gluten free diet, blinded crossover of gluten 5.7 g, fructan 2.1 g or placebo for seven days each. Overall symptom scores 33.1, 38.6 and 34.3, p = 0.04; bloating 9.3, 11.6 and 10.1, p = 0.004. Fructan worse than gluten for overall symptoms (p = 0.049) and bloating (p = 0.003). No difference between gluten and placebo.
Human2015
Randomised clinical study: gluten challenge induces symptom recurrence in only a minority of patients who meet clinical criteria for non-coeliac gluten sensitivity.
Alimentary Pharmacology and Therapeutics
A randomised gluten challenge in patients meeting the clinical criteria for non-coeliac gluten sensitivity. The result is in the published title: symptom recurrence in only a minority of those patients.
Review2017
Suspected Nonceliac Gluten Sensitivity Confirmed in Few Patients After Gluten Challenge in Double-Blind, Placebo-Controlled Trials.
Clinical Gastroenterology and Hepatology
Ten double-blind placebo-controlled gluten challenge trials, 1,312 adults. Only 38 of 231 patients with suspected non-coeliac gluten sensitivity, 16 percent, showed gluten-specific symptoms, and 40 percent had a nocebo response. Challenge duration ran one day to six weeks and doses 2 to 52 g a day, with placebos including starches containing fermentable carbohydrates.
Human2016
Evidence for the Presence of Non-Celiac Gluten Sensitivity in Patients with Functional Gastrointestinal Symptoms: Results from a Multicenter Randomized Double-Blind Placebo-Controlled Gluten Challenge.
Nutrients
The trial pointing the other way, and it belongs here for that reason. A multicentre randomised double-blind placebo-controlled gluten challenge reporting evidence that non-coeliac gluten sensitivity is present in patients with functional gastrointestinal symptoms. A real responder minority is consistent with the pooled analysis above.
Review2024
Retraction notice to "Gluten Does Not Induce Gastrointestinal Symptoms in Healthy Volunteers: A Double-Blind Randomized Placebo Trial" Gastroenterology 2019;157:881-883.
Gastroenterology
The retraction notice for a 2019 trial in healthy volunteers that is still cited in summaries of this topic. PubMed flags the original as a retracted publication. It is listed here so readers who encounter it know not to rely on it.
Human2017
Long term gluten consumption in adults without celiac disease and risk of coronary heart disease: prospective cohort study.
BMJ
64,714 women and 45,303 men without coeliac disease, 26 years, 6,529 coronary events. Highest against lowest fifth of gluten intake: multivariable hazard ratio 0.95 (0.88 to 1.02), p for trend 0.29. Adjusting for whole grains moved it to 1.00; adjusting for refined grains gave 0.85 (0.77 to 0.93), p for trend 0.002. The authors write that gluten free diets should not be promoted in people without coeliac disease.
Human2016
Time Trends in the Prevalence of Celiac Disease and Gluten-Free Diet in the US Population: Results From the National Health and Nutrition Examination Surveys 2009-2014.
JAMA Internal Medicine
The source for how large the gluten-avoiding population is relative to diagnosed coeliac disease in the US across 2009 to 2014. No abstract is indexed in PubMed for this research letter, so no figures are quoted from it here.
Human2022
Nutrient intake differs among persons with celiac disease and gluten-related disorders in the United States.
Scientific Reports
15,610 NHANES participants aged 20 and over, 2009 to 2014, two 24-hour recalls. People without coeliac disease avoiding gluten had lower total carbohydrate and sugar intake, higher beta-carotene and lutein and zeaxanthin, and lower folic acid intake, the last following from wheat flour being the folic acid fortification vehicle.

What people report

These are uncontrolled self-reports, not evidence. They are here because they tell you what to expect and what to watch for, which the trial literature does not. They cannot tell you whether anything works.

Marked and rapid improvement in bloating, pain and fatigue on stopping wheat, reported extremely widely, and reported in the trials too: in the pooled challenge analysis 40 percent of participants reported similar or worse symptoms on placebo.
No change at all, reported by people who tried it on the strength of someone else's experience.
Symptoms returning on accidental exposure to a small amount, which is a common and strongly held report and which the dose-ranging challenge trials did not reproduce in most participants.
Discovering during reintroduction that the trigger was the fermentable carbohydrate rather than the gluten, which is the trial result and is reported by a visible subset of the community.
Weight gain rather than loss after switching to gluten free replacement products, commonly reported and consistent with those products being refined starch.
Being told by a clinician to get tested for coeliac disease first and not doing it, which is the single most consequential thing in this section and which the community discusses openly.
Cost, label vigilance and social difficulty, the three most cited practical complaints and the most common reasons for stopping.

Sources: r/glutenfree and general gastrointestinal communities, coeliac charity patient materials which are careful to distinguish the two populations, and the placebo and nocebo arms of the challenge trials themselves, which are the closest thing to a controlled version of these reports that exists. Uncontrolled self-report otherwise, and in this pattern the self-report and the blinded data disagree more sharply than anywhere else on this site.

Who this is wrong for

Anyone who has not been tested for coeliac disease, and this is the one hard rule on the page. Serology and biopsy both require gluten in the diet to be valid. Starting the diet first can delay the diagnosis for years or make it unreachable without a formal supervised gluten challenge, and coeliac disease is the condition in this area with real consequences if it is missed.
Anyone with alarm features that have not been investigated, including bleeding, unintended weight loss or anaemia. Suppressing symptoms with an elimination diet is the wrong first step when the symptoms might be something that needs finding.
Anyone who feels better off wheat and has not separated gluten from fructans. In the blinded crossover that tested both, fructans produced significantly worse symptoms than gluten and gluten did not differ from placebo. The next test to run is a FODMAP one, not a stricter gluten one.
Anyone relying on fortified wheat products for folic acid, and particularly anyone who could become pregnant. Gluten avoiders without coeliac disease had measurably lower folic acid intake in national survey data, which is a fortification effect rather than a gluten effect and is solvable either way.
Anyone replacing wheat with refined gluten free starch products. The one long cohort found gluten intake was acting as a marker for whole grain intake, and the whole grains are what the association was tracking.
Anyone expecting weight loss. No trial in this population has measured it and no proposed mechanism predicts it.
Anyone with a history of disordered eating, for whom excluding an entire food category with no diagnostic basis and no endpoint is a poor structural fit.

Questions

Is non-coeliac gluten sensitivity real?: In a minority, under blinding, yes. Across ten double-blind placebo-controlled challenge trials covering 1,312 adults, 38 of 231 patients with suspected non-coeliac gluten sensitivity, 16 percent, showed gluten-specific symptoms. In the same pooled analysis 40 percent had a nocebo response, reporting similar or worse symptoms on placebo. There is still no biomarker and no identified mechanism, which is why blinded challenge is the only instrument available.
I feel much better without wheat. Is that gluten?: Possibly not, and there is a specific test for which it is. In a blinded crossover of gluten, fructan and placebo in 59 people already avoiding gluten, fructan produced significantly worse overall symptoms and bloating than gluten did, and gluten did not differ from placebo at all. Fructans are a FODMAP and wheat is a major source of them, so the next thing to test is fermentable carbohydrate rather than a stricter gluten exclusion.
Should I get tested for coeliac disease first?: Yes, before starting, and this is the only hard rule here. Coeliac serology and biopsy both require gluten in the diet to be valid. Going gluten free first makes the diagnosis hard to reach and can require a formal supervised gluten challenge later to get an answer. Coeliac disease is the one condition in this area with a known mechanism, a known marker and real consequences if it goes untreated.
Is a gluten free diet healthier if I don't have coeliac disease?: The one long cohort says no and explains why the question is misleading. Across 110,017 people followed 26 years, gluten intake had no association with coronary heart disease, hazard ratio 0.95, p for trend 0.29. Once refined grain intake was accounted for, higher gluten intake was associated with lower coronary risk, 0.85, because gluten intake was tracking whole grain intake. The authors conclude that gluten free diets should not be promoted in people without coeliac disease.
Is there anything I should watch if I do it anyway?: Folic acid, because wheat flour is the folic acid fortification vehicle in the US and gluten avoiders without coeliac disease had measurably lower intake in national survey data. That matters most for anyone who could become pregnant and it is entirely solvable. The other thing to watch is what replaces the wheat: gluten free replacement products are commonly refined starch with less fibre than what they replace.